欧洲移民群体对疫苗的犹:混合方法系统审查
Erika Khuu1, Sohela Moussaoui2, Nicolas Vignier3
1Sorbonne Université, Faculty of Medicine, Department of Education and Research in General Practice, F75012 Paris, France.
Vaccine
|November 7, 2025
概括
欧洲移民群体对疫苗的犹源于原籍国信仰和东道系统的挑战. 需要文化敏感的干预措施来建立信任并改善不同群体的疫苗接种率.
科学领域:
- 公共卫生 公共卫生
- 社会学 社会学 社会学
- 移民研究 移民研究
背景情况:
- 移民接种疫苗受到中断疫苗接种,不同时间表和边缘化的影响.
- 移民对接种疫苗的犹受独特的文化,结构和经验因素的影响.
研究的目的:
- 系统地审查欧洲移民群体对疫苗犹的定性和定量证据.
主要方法:
- 搜索了八个数据库 (PubMed/MEDLINE,PsycINFO,EMBASE,Scopus,CINAHL,Web of Science,ERIC,Cochrane图书馆) 来查找2000年至2024年的研究.
- 采用乔安娜·布里格斯研究所 (JBI) 的混合方法系统审查方法,使用混合方法评估工具 (MMAT).
主要成果:
- 包括来自西欧/北欧的46项研究 (20项定性,26项定量),涵盖了各种移民群体.
- 综合了研究结果的七个主题:融合文化,对当局的不信任,健康素养,非正式信息网络,社会文化决定因素,社会人口学特征和疫苗特定的感知.
结论:
- 移民对疫苗的犹是源于原产地信仰,宿主规范,移民脆弱性,性别,健康素养,信息网络和不信任的结果.
- 建议与移民社区共同设计的文化响应性,参与性干预措施,解决健康素养和不信任问题.
- 建议进一步研究代表性不足的群体,性别-移民-信任的相互作用,以及世代态度的转变.
相关概念视频
Vaccinations
51.2K
Overview
51.2K
Bias in Epidemiological Studies
1.2K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.2K
Migration
8.7K
Migration is long-range, seasonal movement from one region or habitat to another. This common strategy, carried out by many different organisms around the world, is an adaptive response that typically corresponds to changes in an organism’s environment, like resource availability or climate. Migrations can involve huge groups of thousands of animals as well as single individuals traveling alone and can range from thousands of kilometers to just a few hundred meters.
8.7K
Bioequivalence studies: Biowaivers
211
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
211


